Vertex Pharmaceuticals (NASDAQ:VRTX), a leading biotechnology company with a market capitalization of $113.7 billion, is navigating a critical juncture as it seeks to expand its therapeutic reach and ...

If the drug is approved by the US Food and Drug Administration for the treatment of acute pain in January as expected, the ...

Vertex, a biotechnology company known for its cystic fibrosis treatments, was hurt by a setback in clinical trials for its new therapeutic, suzetrigine, in the chronic pain setting. The company is ...

Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX), with its substantial $114.5 billion market capitalization, continues to dominate the cystic fibrosis (CF) treatment market while advancing a ...

However, Vertex has a big opportunity and has over 50 authorized treatment centers activated. The company expects to share ...

Leerink Partners analyst David Risinger has reiterated their bullish stance on VRTX stock, giving a Buy rating yesterday.Invest with ...

Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) will report its fourth quarter and full year 2024 financial results on Monday, February 10, 2025 after the financial markets close. The company will ...

Vertex Pharmaceuticals Incorporated ... designed to treat the underlying cause of CF, which is in Phase 1 clinical trial; VX-548, a non-opioid medicine for the treatment of acute and neuropathic ...

Vertex, a biotechnology company known for its cystic fibrosis treatments, was hurt by a setback in clinical trials for its new therapeutic, suzetrigine, in the chronic pain setting. The company is ...